


To provide long term capital growth.
| Name | % Net Assets |
|---|---|
| Royal Dutch Shell | 9.7% |
| Royal Dutch Shell | 9.7% |
| GlaxoSmithKline | 7.9% |
| HSBC | 6.2% |
| Vodafone | 5.5% |
| AstraZeneca | 5.0% |
| AstraZeneca | 4.5% |
| Unilever | 4.0% |
| BHP Billiton | 3.9% |
| BG | 3.9% |
| Key | % Net Assets |
|---|---|
| 9.7% | |
| 9.7% | |
| 7.9% | |
| 6.2% | |
| 66.5% |
| Date | 15-Dec-2017 |
|---|---|
| NAV | 80.01p |
| Currency | GBP |
| Change | -0.22p |
| % | -0.27% |
| YTD change | 80.01p |
| YTD % | n/a |
| Fund Inception | 01/08/2008 |
|---|---|
| Fund Manager | Sarah Emly / James Illsley |
| TER | 1.68 (31-Jan-2013) |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | £100 |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | 4.25% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| No risk data available. | |
You are here: research